MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
PerkinElmer Accounts Receivables 2011-2026 | PKI
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables PerkinElmer
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 783 M | 661 M | 662 M | 738 M | 1.18 B | - | 745 M | 633 M | 552 M | 439 M | - | 471 M | 470 M | 457 M | 357 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.18 B | 357 M | 626 M |
Quarterly Accounts Receivables PerkinElmer
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 680 M | 661 M | 617 M | 632 M | 602 M | 597 M | 589 M | 633 M | 645 M | 627 M | 587 M | 613 M | 541 M | 932 M | 942 M | 1.18 B | 948 M | 993 M | 979 M | - | 798 M | 709 M | 626 M | 745 M | 725 M | 725 M | 725 M | 633 M | 633 M | 633 M | 633 M | 552 M | 552 M | 552 M | 552 M | 415 M | 443 M | 436 M | 437 M | - | 414 M | 426 M | 415 M | 471 M | 471 M | 471 M | 471 M | 467 M | 467 M | 467 M | 470 M | 457 M | 457 M | 457 M | 457 M | 357 M | 360 M | 383 M | 345 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.18 B | 345 M | 593 M |
Accounts Receivables of other stocks in the Diagnostics research industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
114 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
1.24 M | - | -6.19 % | $ 10.5 M |  USA |
 |
Bioventus
BVS
|
128 M | $ 8.92 | 0.56 % | $ 594 M | USA |
 |
Castle Biosciences
CSTL
|
51.2 M | $ 26.01 | 0.68 % | $ 722 M | USA |
 |
DexCom
DXCM
|
1.22 B | $ 68.2 | 2.8 % | $ 26.6 B | USA |
 |
Charles River Laboratories International
CRL
|
709 M | $ 154.35 | 1.57 % | $ 7.65 B | USA |
 |
CareDx, Inc
CDNA
|
42.6 M | $ 17.52 | 1.18 % | $ 934 M | USA |
 |
Guardant Health
GH
|
138 M | $ 87.53 | 0.4 % | $ 11 B | USA |
 |
Accelerate Diagnostics
AXDX
|
2.42 M | - | -61.36 % | $ 2.46 M | USA |
 |
Exact Sciences Corporation
EXAS
|
299 M | $ 103.87 | 0.01 % | $ 19.6 B | USA |
 |
Global Cord Blood Corporation
CO
|
416 M | - | - | $ 399 M |  China |
 |
Fulgent Genetics
FLGT
|
69 M | $ 15.53 | 3.88 % | $ 470 M | USA |
|
Biodesix
BDSX
|
8.6 M | $ 17.01 | -1.62 % | $ 2.21 B | USA |
 |
ICON Public Limited Company
ICLR
|
1.34 B | $ 99.43 | 1.86 % | $ 8.2 B |  Irlanda |
 |
Anixa Biosciences
ANIX
|
173 K | $ 2.9 | 2.11 % | $ 94.1 K | USA |
 |
IQVIA Holdings
IQV
|
3.4 B | $ 168.32 | 2.14 % | $ 28.9 B | USA |
 |
Danaher Corporation
DHR
|
3.91 B | $ 194.97 | 1.87 % | $ 139 B | USA |
 |
Biocept
BIOC
|
2.15 M | - | -13.05 % | $ 7.29 M | USA |
 |
Heska Corporation
HSKA
|
29.5 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
1.42 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
735 M | $ 121.42 | 1.79 % | $ 19.3 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.41 B | $ 199.2 | 0.13 % | $ 22.1 B | USA |
 |
QIAGEN N.V.
QGEN
|
381 M | - | - | $ 10.6 B |  Niderland |
 |
Agilent Technologies
A
|
1.17 B | $ 113.43 | 1.43 % | $ 34.5 B | USA |
 |
BioNano Genomics
BNGO
|
4.75 M | $ 1.12 | 0.66 % | $ 1.42 M | USA |
 |
DarioHealth Corp.
DRIO
|
3.16 M | $ 9.28 | 10.24 % | $ 263 M |  Israel |
 |
NeoGenomics
NEO
|
159 M | $ 8.36 | 1.46 % | $ 1.07 B | USA |
 |
Neogen Corporation
NEOG
|
153 M | $ 9.24 | 1.43 % | $ 2 B | USA |
 |
Lantheus Holdings
LNTH
|
359 M | $ 78.46 | -0.05 % | $ 5.3 B | USA |
 |
Chembio Diagnostics
CEMI
|
6.54 M | - | 0.22 % | $ 16.8 M | USA |
 |
Pacific Biosciences of California
PACB
|
35.4 M | $ 1.41 | 3.31 % | $ 423 M | USA |
 |
Co-Diagnostics
CODX
|
304 K | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Medpace Holdings
MEDP
|
402 M | $ 452.71 | -0.21 % | $ 13.1 B | USA |
 |
Motus GI Holdings
MOTS
|
76 K | - | -34.28 % | $ 263 K | Israel |
 |
Mettler-Toledo International
MTD
|
778 M | $ 1 215.3 | 1.35 % | $ 25 B |  Schweiz |
 |
DermTech
DMTK
|
2.58 M | - | -11.32 % | $ 2.94 M | USA |
 |
National Research Corporation
NRC
|
11.1 M | $ 17.95 | 3.16 % | $ 402 M | USA |
 |
Invitae Corporation
NVTA
|
96.1 M | - | - | $ 21.2 M | USA |
 |
Enzo Biochem
ENZ
|
3.99 M | - | -8.98 % | $ 14.8 K | USA |
 |
Natera
NTRA
|
244 M | $ 199.43 | 0.89 % | $ 19.6 B | USA |
 |
OPKO Health
OPK
|
118 M | $ 1.2 | 0.42 % | $ 833 M | USA |